Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization

Autor:	Yugenia K. Hong-Nguyen, Joseph Toerner, Lucia Lee, Maria C. Allende, David C. Kaslow
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	npj Vaccines, Vol 9, Iss 1, Pp 1-3 (2024)
Druh dokumentu:	article
ISSN:	2059-0105
DOI:	10.1038/s41541-024-01002-y
Popis:	Abstract In August 2023, FDA approved Abrysvo for active immunization of pregnant individuals at 32 through 36 weeks gestational age to prevent lower respiratory tract disease (LRTD), including severe LRTD, caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. A pragmatic approach to narrow the interval of use of Abrysvo in pregnant individuals balanced benefits of vaccine effectiveness against potential risks to infant and mother.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/b1c082fe06f04592bb451be24cb56ade Zobrazit plný text záznamu Full text from SpringerLink View record in DOAJ